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Figure 1. Prevalence of analgesics consumption during pregnancy from different parts of the world. 
Percentages summarised here as reported by the literature. More details on each study can be found in 
Table 1 and in text. 
338x190mm (300 x 300 DPI) 
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Figure 2. Schematic diagram of the major drug transporters on human placental syncytiotrophoblast and 
their substrates according to medication type. Solute-linked carrier (SLC) (blue) and adenosine triphosphate 
binding cassette (ABC) transporters (red). Phase I metabolising enzymes (P1); phase II metabolising 
enzymes (P2). Arrow direction demonstrates influx/efflux. Note that not all substrates have been examined 
in the human placenta. Figure was prepared based on information cited in this review. * exact placental 
membrane localisation not known; † localised on both membranes 
338x190mm (300 x 300 DPI) 
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Figure 3. OTC analgesic exposures during pregnancy and their associations with adverse offspring health 
outcomes from current literature. Indication of references according to study type: * Cohort Studies, § 
Case-control/Case Report Studies, ¥ Systematic reviews/Meta-analyses, † Experimental Studies 
338x190mm (300 x 300 DPI) 
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Table 1. Proportion of women using analgesics during pregnancy. Data from various studies across global regions.











Lind et al., 2017
Netherlands 2002-2006 All trimesters 3,184 Questionnaires 29.9 Paracetamol
other
Snijder et.al., 2012






Bremer et al., 2017
France 2003-2006 1st and 2nd trimester 895 Questionnaires 81 Paracetamol
Ibuprofen 
Aspirin
Philippat et al., 
2011
Italy 2016-2017 All trimesters 503 Questionnaires 69.7 Paracetamol Navaro et al., 2018
Europe
Serbia 2009-2010 1st and 2nd trimester 311 Questionnaires 6.4 Paracetamol Odalovic et al., 
2012









Headley et al., 2004
Europe, Australia, 
America








Lupattelli et al., 
2014






Werler et al., 2005




















Bercaw et al., 2010
United Arab 
Emirates
October to December 
2016












Al Bahhawi et al., 
2018
Middle East
Iran Not specified Not specified 180 Questionnaires >35 General OTC medication Baghianimoghadam 
et al., 2013
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Bohio et al., 2016






Mohammed et al., 
2013




Kebede et al., 2009 
Africa
Nigeria Not specified All trimesters 518 Questionnaires 30.3 Not specified Abasiubong et al., 
2012
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(Renes et al., 
1999; Olson et 
al., 2002)









(Bakos et al., 
2000; St-Pierre 
et al., 2000; 













Azzaroli et al., 
2007; Ni and 
Mao, 2011)








(Ritter et al., 
2005; Azzaroli 






ABCC5 Basal Efflux Antineoplastic 
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OCT3/SLC22A3 Basal bidirectional Cationic drugs, 
nicotine, 
amphetamine
(Sata et al., 
2005; Lee et 
al., 2018)









al., 2013; Yang 
et al., 2016)











al., 2013; Yang 
et al., 2016)














(Tamai et al., 
2000; Fujiwara 
et al., 2001)
OAT4/SLC22A11 Basal Influx NSAIDs Antihypertensive 
compounds
(Cha et al., 




2007; Nigam et 
al., 2015; 
Noguchi et al., 
2015)









2007; Reese et 
al., 2016)
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Table 3. Studies on neurodevelopmental offspring outcomes following in utero exposure to OTC analgesics
Study details Results
Outcome Category Analgesic Study 
time
Study type Cohort Data collection method Main study results Study
Neurodevelopment




Telephone interviews Higher risk for 
ADHD-like 
behaviours and HKDs 
in children
(Liew et al., 
2014)






reports of children ADHD 
symptoms
Higher risk for ADHD 




























Searches in MEDLINE, 
Embase and Cochrane 
databases



















Searches in PubMed, 
Embase, Web of Science 
and Cochrane databases







Questionnaires Higher risk for 
adverse 
neurodevelopmental 
outcomes at the age 
of 3 years 
(Brandlistuen et 
al., 2013)
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Telephone interviews Higher risk for ASD 
with hyperkinetic 
symptoms
(Liew et al., 
2016)




Questionnaires Adverse association 
with pre-school 
children behaviour














language delay in 
















Higher risk for 
spastic CP











Decrease in IQ levels 


















Interviews Increased incidence 
of NTDs when 
consumed to treat 
flu symptoms
(Lynberg et al., 
1994)










(Marret et al., 
2010)
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outcomes in preterm 
babies




Interviews and follow-up 
examinations of children
No association with 
decreased IQ levels 




















Interviews Increased risk of 
preterm infants 
developing CP
(Tyler et al., 
2012)
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Higher risk for 
asthma 
development at 
3 and 7 years of 
age
Iburofen: Higher 
risk for asthma 
development at 
3 years of age
(Magnus et al., 
2016)










3 and 5 years of 
age
(Sordillo et al., 
2015)








(Kang et al., 
2009)














for wheeze in 
children 
between 2.5 and 
7 years of age
(Eyers et al., 
2011)
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Paracetamol Not specified Randomised 
controlled trial
345 participants Questionnaires Higher risk for 
wheeze during 
the 1st  year of 
age
(Persky et al., 
2008)
Paracetamol 1998-2006 Prospective 
cohort study
301 participants Questionnaires Association of 
use during 
middle and late 
pregnancy with 
offspring 
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Testes Ibuprofen n/a Ex-vivo and 
xenograft 
systems
First and second 
trimester human 
fetal testes
n/a Altered germ 
cell biology and 
had endocrine 
disrupting 
effects on first 
trimester testes













































Paracetamol 2001-2009 Prospective 
cohort study
343 participants Questionnaires Exposure during 
8-14 weeks was 
associated with 
shorter AGD














(Lind et al., 
2017)













Higher risk for 
hypospadias 
when consumed 
during the 1st 
trimester
(Correy et al., 
1991)






Interviews Higher risk for 
hypospadias
(Lind et al., 
2013)




















(Slone et al., 
1976)










Higher risk for 
cryptorchidism 
when consumed 





(Snijder et al., 
2012)
Paracetamol n/a Xenograft 
system







Driesche et al., 
2015)






Higher risk for 
cryptorchidism 
(Jensen et al., 
2010)
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when used for 
more than 4 
weeks during 







903 participants Questionnaires No significant 
association with 
cryptorchidism
(Philippat et al., 
2011)
Ovaries Ibuprofen n/a Ex-vivo system 185 human fetal 
ovaries
n/a Effect on ovarian 
cell proliferation 














Gonzalez et al., 
2018)










(Ernst et al., 
2019)
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closure from 12 
papers
Searches in 











(Allegaert et al., 
2019)





(Aker et al., 
2015)




Interviews Association with 
cardiac defects 




Paracetamol 1997-2011 Case-control 
study
29,078 birth 
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Diclofenac Not specified Case report 2 cases Case description Oligohydramnios 
on both cases 









(Phadke et al., 
2012)









fluid volume or 
fetal urine 
output
(Maher et al., 
1993)








during 1st and 
2nd trimester





(Dathe et al., 
2019)
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Higher risk of 
miscarriage
(Li et al. , 2003)










(Dathe et al., 
2018)










(Daniel et al., 
2014)








(Edwards et al., 
2012)
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Paracetamol 1976-1998 Case-control 
study
73 cases with 
amnion rupture 
sequence









Higher risk for 
amnion rupture 
sequence when 
used during the 
1st pregnancy 
trimester
(Werler et al., 
2003)










with growth of 
the fetus during 
pregnancy






















(Werler et al., 
2002)














Higher risk for 
gastroschisis 
when consumed 
during the 1st 
trimester
(Kozer et al., 
2002)














Higher risk for 
gastroschisis 
when consumed 
during the 1st 
trimester 
(Torfs et al., 
1996)














during the 1st 
trimester
(Cassina et al., 
2010)
















during the 1st 
trimester
(Padberg et al., 
2018)





identified in the 








during the 1st 
trimester
(van Gelder et 
al., 2011)
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NSAIDs 1997-2001 Case-control 
study
29,078 birth 
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32 Background: Analgesia during pregnancy is often necessary. Due to their 
33 widespread availability, many mothers opt to use over-the-counter (OTC) analgesics. 
34 Those analgesic compounds and their metabolites can readily cross the placenta 
35 and reach the developing fetus.  Evidence for safety or associations with adverse 
36 health outcomes is conflicting, limiting definitive decision-making for healthcare 
37 professionals. 
38 Objective and rationale: This review provides a detailed and objective overview of 
39 research in this field. We consider the global prevalence of OTC analgesia during 
40 pregnancy, explain current mechanistic understanding of how analgesic compounds 
41 cross the placenta and reach the fetus, and review current research on exposure 
42 associations with offspring health outcomes.
43 Search Methods: A comprehensive English language literature search was 
44 conducted using PubMed and Scopus databases. Different combinations of key 
45 search terms were used including “over-the-counter/non-prescription analgesics”, 
46 “pregnancy”, “self-medication”, “paracetamol”, “acetaminophen”, “diclofenac”, 
47 “aspirin”, “ibuprofen”, “in utero exposure”, “placenta drug transport”, “placental 
48 transporters”, “placenta drug metabolism” and “offspring outcomes”. 
49 Outcomes: This article examines the evidence of fetal exposure to OTC analgesia, 
50 starting from different routes of exposure to evidence, or the lack thereof, linking 
51 maternal consumption to offspring ill health. There is a very high prevalence of 
52 maternal consumption of OTC analgesics globally, which is increasing sharply. The 
53 choice of analgesia selected by pregnant women differs across populations. Location 
54 was also observed to have an effect on prevalence of use, with more developed 
55 countries reporting the highest consumption rates. Some of the literature focuses on 
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56 the association of in utero exposure at different pregnancy trimesters and the 
57 development of neurodevelopmental, cardiovascular, respiratory, reproductive 
58 defects. This is in contrast to other studies which report no associations. 
59 Wider implications: The high prevalence and the challenges of reporting exact 
60 consumption rates make OTC analgesia during pregnancy a pressing reproductive 
61 health issue globally. Even though some healthcare policy-making authorities have 
62 declared consumption of some OTC analgesics for most stages of pregnancy safe, 
63 such decisions are often based on partial review of literature. Our comprehensive 
64 review of current evidence highlights that important knowledge gaps still exist. Those 
65 areas require further research in order to provide pregnant mothers with clear 
66 guidance with regard to OTC analgesic use during pregnancy.
67
68 Keywords: over-the-counter; non-prescription; analgesics; fetal exposure; 
69 acetaminophen; paracetamol; ibuprofen; aspirin; diclofenac; pregnancy
70




72 There is almost a complete lack of safety and efficacy profiling of medications during 
73 pregnancy. This includes failure to consider differences in fetal function and 
74 sensitivity to exogenous exposures depending upon gestational age or fetal sex. 
75 Since the exact mechanisms of action for many medications are not fully understood, 
76 drugs are best generally avoided during pregnancy when possible (Adam et al., 
77 2011). There are, however, some conditions that demand the use of prescription or 
78 over-the-counter (OTC) medications (Källén and Reis, 2016; Mitchell et al., 2011). 
79 The majority of women use at least one type of OTC medications during the course 
80 of their pregnancy, with analgesics being one of the most prevalent. OTC analgesics 
81 are generally considered safe at the recommended doses; however, dosage and 
82 frequency completely depend on the mother, and can vary with different levels of 
83 knowledge, often resulting in uncertainty and concern (Damase-Michel et al., 2009; 
84 Pijpers et al., 2017). The task of consulting and awareness-raising therefore falls on 
85 healthcare professionals. Such advice can sometimes, as in the case of developing 
86 countries, be based on inadequate knowledge (Alrabiah et al., 2017; Pallivalapilla et 
87 al., 2018). 
88
89 Adverse side effects of OTC analgesics overconsumption in the adult are well 
90 known. Indeed, the association of paracetamol (also known as acetaminophen) 
91 overdose with liver failure and consequences of chronic use (Roberts et al., 2016), 
92 have been exploited in the past, making paracetamol the most commonly used 
93 compound in self-poisoning in the US and UK (Kozer and Koren, 2001). Other OTC 
94 analgesics such as aspirin, non-steroidal anti-inflammatory drugs (NSAID), and their 
95 combinations with other drugs, can also have adverse effects on the cardiovascular 
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96 system and gastrointestinal tract of the adult. In sharp contrast there is a lack of 
97 adequate information regarding the safety of these medications during pregnancy, 
98 for both the mother and the fetus, which raises serious public health concerns (Adam 
99 et al., 2011). In this review, we discuss the prevalence of OTC analgesic 
100 consumption during pregnancy on a global scale. We describe trans-placental 
101 transport, as well as providing an overview of the current literature on the 
102 associations of in utero exposure and offspring postnatal ill health.
103
104 Global prevalence of OTC analgesics amongst pregnant women 
105 The reality is that physicians recommend paracetamol to pregnant women to deal 
106 with common pregnancy symptoms, as it is considered to be the mildest and safest 
107 analgesic with the lowest risks of teratogenicity (Black and Hill, 2003). Paracetamol 
108 was classified as a “Pregnancy Category B” drug by the FDA in 2005 
109 (www.fda.gov/Drugs). Members of this category were defined as a substance for 
110 which “animal reproduction studies have failed to demonstrate a risk to the fetus and 
111 there are no adequate and well-controlled studies in pregnant women”. It has been 
112 known for many years that paracetamol can readily cross the placenta, as high 
113 concentrations and have been detected in fetal plasma samples, sometimes at levels 
114 matching those seen in the maternal liver (Byer et al., 1982; Nitsche et al., 2017). 
115 More widely, most NSAIDs can cross the placenta. Therefore, not only paracetamol, 
116 but other analgesics and their metabolites, can potentially have a direct effect on the 
117 developing fetus. 
118
119 Indications of analgesics use without prescription during pregnancy are hard to 
120 quantify, as they are often subjective decisions of the mother. Most studies 
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121 assessing frequency of use during pregnancy and associations with adverse health 
122 outcomes in the offspring, very rarely take into account the reason of consumption in 
123 each case. They can vary from headaches, fever, injuries, infections, pregnancy-
124 related pain, to chronic migraines or other secondary underlying conditions such as 
125 rheumatoid arthritis (Lalkhen and Grady, 2008; Negro et al., 2017; Ray-Griffith et al., 
126 2018; Rivera Díaz and Lopera Rivera, 2012). Type and timing of the symptoms also 
127 determine short- or long-term use of analgesic compounds. Maternal pain relief from 
128 such conditions contributes towards physical and psychological well-being, which are 
129 important factors for an uneventful pregnancy. Individual compounds are used for 
130 the treatment of different conditions. Paracetamol is mainly used for its analgesic 
131 and antipyretic properties amongst pregnant women. NSAIDs, such as ibuprofen or 
132 diclofenac, are used to treat mild to moderate pain and fever. Aspirin can sometimes 
133 have a more specific purpose as it is often prescribed to treat conditions such as pre-
134 eclampsia, recurrent miscarriages, fetal growth restriction (Atallah et al., 2017; 
135 Belhomme et al., 2017; Roberge et al., 2016). Over the counter, aspirin is also used 
136 as a painkiller and anti-inflammatory agent during pregnancy. 
137
138 Quantifying the prevalence of OTC (non-prescription) analgesics consumption in 
139 pregnancy is not an easy task. A role in this has the fact that most studies on the 
140 topic fail to define whether consumption of such compounds that are available OTC 
141 occurs through maternal initiative, doctor prescription, or both. Studies from different 
142 countries around the world have employed approaches such as questionnaires, 
143 interviews and patient information systems in an attempt to measure consumption. 
144 Percentages of OTC analgesics use during pregnancy from different countries are 
145 summarised in Figure 1. A recent systematic review and meta-analysis, including 13 
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146 studies from African and Asian countries, reported an estimated overall prevalence 
147 of self-medication during pregnancy at 32% (Mohseni et al., 2018). In contrast, a 
148 multinational study on 9,459 women in Western Europe (Italy, Austria, Switzerland, 
149 France, United Kingdom, The Netherlands), Northern Europe (Norway, Sweden, 
150 Finland, Iceland), Australia, South America and North America (USA, Canada), 
151 showed that 50.6% used one or more types of OTC analgesics during pregnancy, 
152 with paracetamol being used most commonly (Lupattelli et al., 2014). A previous 
153 USA study revealed a similarly high percentage of 65.5% out of 10,533 pregnant 
154 women using paracetamol, some in combination with NSAIDs (Werler et al., 2005). 
155 Another study in the USA investigated first trimester consumption by 5,381 mothers 
156 of healthy infants, and reported similar percentages (Thorpe et al., 2013). In Texas, a 
157 study, including only 485 Hispanic women, reported a general OTC medication use 
158 of 23%, with paracetamol, ibuprofen and aspirin used in 13%, 4% and 3% of the 
159 cases respectively (Bercaw et al., 2010). Most European countries have shown year 
160 on year increases in analgesics sales over the past 30 years (Kristensen et al., 
161 2016). This is reflected in the high consumption rates of pregnant women in these 
162 populations.In Europe, A a Danish study reported that almost 40% out of 1,027 
163 women reported using paracetamol during pregnancy, while only 4.4% used 
164 ibuprofen or aspirin (Lind et al., 2017). A smaller study in France, analysing aspirin, 
165 paracetamol and ibuprofen use, showed that 81% out of 895 pregnant women used 
166 these compounds (Philippat et al., 2011). In the Netherlands, 29.9% of 3,184 
167 women, used mild analgesics at some point during their pregnancy (Snijder et al., 
168 2012). In neighbouring Germany, a more recent study of 518 women with singleton 
169 pregnancies, reported a 47.3% frequency of analgesics use, with paracetamol being 
170 again the most prevalent (Bremer et al., 2017). In the UK, a study including 14,199 
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171 pregnancies reported 39.6%, 39.2% and 30.9% use of analgesics during the 1st, 2nd 
172 and 3rd trimester respectively (Headley et al., 2004). Paracetamol was used most 
173 commonly, 10-15 times more than the next most frequently used compound. A study 
174 in southern Italy found that the most commonly used OTC medication was again 
175 paracetamol, consumed by 69.7% of 503 pregnant women. Interestingly 86.7% of 
176 these women reported that they were willing to self-medicate in case of a non-
177 serious health problem (Navaro et al., 2018). In contrast, a considerably lower 
178 percentage of women consuming paracetamol during pregnancy (6.4%) was 
179 reported in a study from Serbia (Odalovic et al., 2012). This could be a result of 
180 differences in socio-demographic characteristics of the population in this country 
181 compared to the majority of the rest European countries (Mihailovic et al., 2018).
182
183 A small study in United Arab Emirates reported 55.1% and 10.3% out of 140 
184 pregnant women using paracetamol and ibuprofen respectively (Abduelkarem and 
185 Mustafa, 2017). Among 100 pregnant women in Saudi Arabia, the most prevalent 
186 OTC analgesic was aspirin (14%), while paracetamol and ibuprofen were used less 
187 frequently (Al Bahhawi et al., 2018). In the developing country of Pakistan, a study in 
188 Hyderabad included 351 women and reported 43.6% of paracetamol, 3.8% ibuprofen 
189 and 1.5% aspirin use during their pregnancies (Bohio et al., 2016). A surprisingly 
190 high percentage of 77.4% of these women had no knowledge about the medicines 
191 they were choosing to use, including indications for use, doses and potential adverse 
192 side-effects. General OTC medication use among 180 pregnant women in Iran was 
193 higher than 35%; however, this study did not mention specific compounds 
194 (Baghianimoghadam et al., 2013). An Ethiopian study including 339 women, showed 
195 an OTC analgesics prevalence of 40.1% during pregnancy (Mohammed et al., 
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196 2013). In a larger study from the same country, general self-medication during 
197 pregnancy was reported for 12.4% out of 1,268 women, from who 19.2% and 1.9% 
198 used paracetamol and aspirin respectively (Kebede et al., 2009). In Nigeria, OTC 
199 analgesics were found to be used by 30.3% out of 518 pregnant women 
200 (Abasiubong et al., 2012).
201 Overall, as summarised in Table 1, there is a high global prevalence of OTC 
202 analgesic consumption during pregnancy. Because of the abundance and ease of 
203 access to these compounds, reported percentages might underestimate actual 
204 consumption levels, as most of these studies based their findings on questionnaires 
205 and/or interviews. In addition, under/overrepresentation of women of a certain 
206 educational level should not be overlooked when comparing populations from 
207 different countries. Nevertheless, at present cohort studies are the best tool to 
208 evaluate the frequency and dosage of analgesic use during pregnancy 
209
210 It is important to note that overall OTC analgesic consumption in the general 
211 population is high (Porteous et al., 2005; Samuelsen et al., 2015; Sarganas et al., 
212 2015; Turunen et al., 2005). Some studies even report that women self-medicate 
213 more frequently than men, and this includes women of reproductive age (Dal Pizzol 
214 et al., 2019; Dale et al., 2015). OTC analgesics consumption has also been reported 
215 in pre-pregnancy cohorts of men and women trying to conceive (Palmsten et al., 
216 2018). Therefore, a point to consider is that prospective pregnancies (pre-
217 conception) could potentially be affected by early analgesic consumption, even 
218 before the individuals are aware of their pregnancy. However, we could not find any 
219 pre-pregnancy cohort studies assessing OTC analgesics consumption to date. 
220
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221 The feto-maternal interface and analgesics transport 
222 Maternal and fetal blood circulations are separated throughout pregnancy (Boyd and 
223 Hamilton, 1970). However, essential communication between these two plasma units 
224 facilitates pregnancy maintenance, nutritional exchange and removal of fetal waste 
225 products, all utilising the placenta as a physical link. The placenta consists of 
226 endothelial cells of the fetal capillaries (basal membrane, fetal side) and 
227 syncytiotrophoblast cells (apical membrane, maternal side) (Elad et al., 2014). There 
228 are several mechanisms that facilitate feto-maternal communication depending on 
229 the nature of the molecule that is being transported. Specific transport can be by 
230 hydrophilic or lipophilic diffusion, and in some cases protein-mediated transport. 
231 Smaller molecules that have a maternal-fetal concentration gradient tend to simply 
232 diffuse across the placenta. The diffusion rate depends on the permeability and 
233 thickness of the placenta, the surface area available and the concentration 
234 difference. These parameters have been defined by a diffusion equation known as 
235 “Fick’s law” that is used to calculate the net rate of diffusion for any solute (Sibley et 
236 al., 2004). In addition, studies in rabbits have shown that despite the anatomical 
237 properties of the placenta, the fetal endothelium has a key role in determining drug 
238 transfer. This was also later described in humans by Elad and colleagues, which is 
239 biologically plausible, bearing in mind that these two species share the same 
240 hemochorial type of placenta (Elad et al., 2014).
241
242 Physiology and absorption, distribution, metabolism and excretion of drugs and their 
243 metabolites are altered during pregnancy and contribute to a change in maternal 
244 drug pharmacokinetics (Costantine, 2014; Feghali et al., 2015; Kazma et al., 2020; 
245 Pinheiro and Stika, 2020; Sen et al., 1998). Major changes in many organ systems 
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246 result in an altered maternal pharmacokinetic and pharmacogenomic profile during 
247 pregnancy; however, there are still many knowledge gaps on the topic (Betcher and 
248 George, 2020; Pariente et al., 2016). Gastrointestinal tract changes including 
249 common pregnancy symptoms such as constipation and gastric emptying, can 
250 impact drug absorption (Levy et al., 1994; Quinlan and Hill, 2010). Cardiac output, 
251 stroke volume, plasma volume, vascularity and blood flow to the uterus are also 
252 increased during pregnancy, which affect drug distribution (Capeless and Clapp, 
253 1991; Pacheco et al., 2013; Pirani et al., 1973; Qasqas et al., 2004). In addition, the 
254 activity of several key phase I and II metabolising enzymes change during 
255 pregnancy, resulting in an altered drug metabolism (Betcher and George, 2020). 
256 Drug elimination is also increased during pregnancy through the increase in 
257 glomerular filtration rate (GFR) and overall renal elimination rate (Davison and 
258 Dunlop, 1984; Dunlop, 1981; Frederice et al., 2013). Finally, changes in placental 
259 transporter protein expression, further alter drug transport during pregnancy (Mathias 
260 et al., 2005; Sun et al., 2006). There are several approaches in the literature with 
261 pharmacokinetic models predicting and quantifying these changes during pregnancy 
262 (Van Hasselt et al., 2012; Jeong and Stika, 2020; Ke et al., 2014). A very relevant 
263 example is a study by Mian and colleagues, where paracetamol pharmacokinetics 
264 during pregnancy was successfully predicted using models in pregnant and non-
265 pregnant women (Mian, Allegaert, et al., 2020).
266
267 As described, many drugs freely cross the placenta and reach the developing fetus. 
268 A number of researchers have been focusing on studying this ethically and 
269 practically constrained topic. In vitro models and animal studies are used in most 
270 cases, although extrapolation of results to humans can be problematic. Several in 
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271 vitro and in vivo models have been developed to study placental drug transfer and 
272 metabolism. In vitro models include placental cotyledon perfusion and cell cultures 
273 using placental explants, syncytiotrophoblasts, microvillus membrane vesicles and 
274 human placental choriocarcinoma cells (Syme et al., 2004). In vivo studies in 
275 pregnant women have ethical and methodological restrictions limiting them to blood 
276 sampling from the mother (any peripheral vein) and the fetus (umbilical cord in the 
277 peri/post delivery period) for drug concentration ratio measurements. Animal in vivo 
278 models have been extensively used including experiments in mice, rats, sheep, 
279 rabbits, guinea pigs, and -for a closer to human approach- baboons and monkeys 
280 (e.g. macaques). Some studies have assessed coelomic and amniotic fluids, hair 
281 and meconium samples from the fetus to analyse intrauterine exposure to drugs and 
282 drug metabolites (Jauniaux and Gulbis, 2000; Ostrea et al., 1989). The human 
283 placental perfusion model is another non-invasive way used to predict placental drug 
284 transfer in vivo (Hutson et al., 2011). This method was used recently ex vivo on 
285 human term placenta to show the passive diffusion of paracetamol and the faster 
286 transport of two paracetamol metabolites through transporters (Conings et al., 2019). 
287 A pharmacokinetic prediction model was developed recently to predict placental 
288 transfer, fetal metabolism and clearance of paracetamol (Mian, van den Anker, et al., 
289 2020). 
290
291 Drugs in maternal plasma often exist in either an ionized form or bound to plasma 
292 proteins (serum albumin, lipoproteins, globulins, glycoproteins, etc) as well as being 
293 subject to transformation through oxidation, sulphation and/or glucuronidation. Only 
294 active drugs can diffuse through the placenta, meaning they must be unbound and 
295 unionized, unless they are transported in a conjugated form. While some drugs travel 
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296 across the placenta through various active transport proteins, the majority, in their 
297 intact state, cross the placenta by simple diffusion and are governed by Fick’s Law of 
298 Diffusion. In general, hydrophobic compounds with a molecular weight of <500 Da 
299 can easily diffuse through the placenta. In the case of OTC analgesics, most 
300 compounds range between a molecular weight of 150 to 250 Da. Paracetamol for 
301 example has a molecular weight of 151.1 Da and can therefore readily diffuse across 
302 the placenta. It is a process that does not require an energy input as it utilizes the 
303 kinetic energy from these molecules and goes on until a concentration equilibrium is 
304 reached. A similar mechanism is used for the transport of NSAIDs. Paracetamol, 
305 aspirin and ibuprofen, being weak acids and lipid-soluble can all therefore cross the 
306 placental barrier and enter fetal circulation (Adams et al., 1969; Alano et al., 2001; 
307 Jacobson et al., 1991; Leverrier-Penna et al., 2018; Naga Rani et al., 1989; Shintaku 
308 et al., 2009; Siu et al., 2000; Weigand et al., 1984).
309 Some of the metabolites of analgesics are, however, substrates for drug transporters 
310 and can therefore be part of drug-drug interactions. For example, the transport of 
311 paracetamol metabolites is facilitated by ATP-binding cassette (ABC) transporters. 
312 More specifically, secretion of paracetamol-glucuronide relies on ABCC2, ABCC3 
313 and ABCG2 membrane transporters, while paracetamol-sulphate can also be 
314 excreted via the ABCC4 transporter (Xiong et al., 2000, Xiong et al., 2002; Chen et 
315 al., 2003; Manautou et al., 2005; Zamek-Gliszczynski et al., 2005, Zamek-
316 Gliszczynski et al., 2006a; Zamek-Gliszczynski et al., 2006b; Lee et al., 2009). 
317 ABCB1, ABCC1, ABCC4, ABCC5 and ABCG2 transporter expression was 
318 upregulated in patients after a toxic dose of paracetamol, suggesting that they might 
319 also play a role in paracetamol excretion (Barnes et al., 2007). In addition, cell line 
320 assays showed that paracetamol can interfere with solute carrier transporters (SLC), 
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321 mediating their excretion/uptake properties resulting in drug-drug interactions 
322 (Khamdang et al., 2002). As mentioned before, ibuprofen can diffuse through 
323 membranes without any transport proteins, but not much is known about specific 
324 transport of its metabolites. Both S- and R-ibuprofen enantiomers are, however, 
325 inhibitory substrates for SLC transporters, leading to drug-drug interactions 
326 (Khamdang et al., 2002; Itagaki et al., 2006; Chu et al., 2007; Omkvist et al., 2010; 
327 Honjo et al., 2011; Wang et al., 2012). Finally, aspirin metabolites are excreted by 
328 SLC22A6 and interact with SLC22A8 and ABCB1 transporters (Apiwattanakul et al., 
329 1999; Kugai et al., 2013; Oh et al., 2014; Wang et al., 2014; Parvez et al., 2017).
330
331 Drug transporters in the placenta
332 Many drug-transporter proteins are expressed in the placental barrier and regulate 
333 fetal exposure to drugs and their substrates, by either blocking or facilitating trans-
334 placental transport (Iqbal et al., 2012; Walker et al., 2017). They are found on both 
335 apical (syncytial microvillous) and basal membranes, on the maternal and fetal side 
336 respectively (Figure 2), and have a large range of drug substrates (Table 2). They 
337 belong primarily to two super-families: the solute-linked carrier transporter proteins 
338 (SLC) and the ATP-dependent binding cassette transporter proteins (ABC) 
339 (Rubinchik-Stern and Eyal, 2012). 
340
341 ABC transporters that have been detected in the human placenta are: 
342 phosphoglycoprotein (P-gp/ABCB1), breast cancer resistance protein 
343 (BCRP/ABCG2) and multidrug resistance-associated protein (MRP/ABCC) 
344 transporters (Figure 2). ABCB1 transporter is located on the apical membrane of 
345 syncytiotrophoblasts throughout gestation, with even higher placental gene mRNA 
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346 levels than liver and kidney in rats (Atkinson et al., 2003; Ceckova-Novotna et al., 
347 2006; Cordon-Cardo et al., 1990; Leazer and Klaassen, 2003; Nagashige et al., 
348 2003; St.-Pierre et al., 2000). ABCG2, similar to ABCB1, is also highly expressed on 
349 lipid rafts in the apical cell membrane of syncytiotrophoblasts (Litman et al., 2002; 
350 Mao, 2008; Szilagyi et al., 2017). Interestingly, apart from its drug transport 
351 properties in the placenta, ABCG2 facilitates trophoblast cell differentiation and 
352 survival. When ABCG2 is silenced in placenta cell cultures, higher rates of apoptosis 
353 occur, as well as changes in differentiation processes through β-hCG and HERV-W 
354 expression reduction (Evseenko et al., 2007). 
355
356 ABCC1, 2, 3, 4 and 5 transporter proteins have also been localised on the surface of 
357 human placental syncytiotrophoblast cells. ABCC1 has been localised on both the 
358 apical and basal membranes of syncytiotrophoblasts in term placenta samples 
359 (Afrouzian et al., 2018; Nagashige et al., 2003; St.-Pierre et al., 2000). ABCC2 is 
360 located on the apical membrane of syncytiotrophoblasts and has over 30 known 
361 substrates, including paracetamol metabolites (Bakos et al., 2000; St.-Pierre et al., 
362 2000; Meyer Zu Schwabedissen et al., 2005a). ABCC3 efflux transporter is also 
363 located on the apical membrane and its substrates include paracetamol metabolites 
364 (St.-Pierre et al., 2000; Azzaroli et al., 2007; Ni and Mao, 2011). ABCC4 transporter 
365 was found on the apical membrane, and facilitates efflux of some paracetamol 
366 metabolites as well (Ritter et al., 2005; Azzaroli et al., 2007; Russel et al., 2008). 
367 Finally, ABCC5 efflux transporter is found on the basal membrane of placental 
368 syncytiotrophoblast cells with a more modest list of substrates (Meyer zu 
369 Schwabedissen et al., 2005b). 
370
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371 SLC transporters in the human placenta include organic ion transporters and 
372 monoamine transporters (Figure 2). Organic cation transporters can either be 
373 potential-sensitive (OCTs) or proton gradient-driven (OCTNs). OCT3/SLC22A3 
374 localises on the basal membrane of syncytiotrophoblast cells and is involved in the 
375 bidirectional transport of several cationic drugs and exogenous compounds including 
376 nicotine and amphetamine (Lee et al., 2018; Sata et al., 2005). OCTN1/SLC22A4 
377 and OCTN2/SLC22A5 share very similar sequence homology and are both located 
378 on the apical membrane (Ganapathy and Prasad, 2005; Grigat et al., 2009; Grube et 
379 al., 2005). Two organic anion-transporting polypeptides (OATPs) are also found in 
380 the placenta, OATP2B1/SLCO2B1 and OATP4A1/SLCO4A1. SLCO2B1 influx 
381 transporter is found primarily on the basal membrane (Roth et al., 2012; St.-Pierre et 
382 al., 2000; Ugele et al., 2003). SLCO4A1 is another influx transporter that spans the 
383 apical membrane (Fujiwara et al., 2001; Tamai et al., 2000). Organic anion 
384 transporter 4 (OAT4/SLC22A11) is expressed in the basal membrane of human 
385 placental syncytiotrophoblasts and facilitates import of anionic drugs including some 
386 NSAIDs (Cha et al., 2000; Nigam et al., 2015; Noguchi et al., 2015; Rizwan and 
387 Burckhardt, 2007; Ugele et al., 2003).
388
389 OAT1/SLC22A6 efflux transporter is also expressed in human placenta; however, 
390 exact location was not specified (Hosoyamada et al., 1999). Although no literature 
391 was found that reported OAT3/SLC22A8 expression in human placenta, it has 
392 previously been detected in rat placenta (Leazer and Klaassen, 2003). Monoamine 
393 transporters in the placenta include the serotonin transporter (SERT/SLC6A4) and 
394 the norepinephrine transporter (NET/SLC6A5), both expressed on the apical 
395 membrane of syncytiotrophoblasts. 




397 After a compound crosses the placenta, it reaches the fetal plasma and is distributed 
398 systemically. In general, placental blood is delivered to the fetal liver (where it 
399 provides 70% of the blood supply) and, through the ductus venosus and foramen 
400 ovale, straight to the heart, from where it is sent to the brain and upper extremities 
401 (Godfrey et al., 2012). It is thought that a similar distribution path is followed by the 
402 drugs that cross the placenta. Therefore, they can have a direct effect on these 
403 tissues.
404
405 Drug metabolising enzymes in the placenta
406 Before reaching the fetus, medications can be processed by the placental drug 
407 metabolising machinery, either posing risks for transport of toxic metabolites or 
408 having a potential protective effect through deactivation of toxic agents. The placenta 
409 contains enzymes that facilitate drug oxidation, reduction, hydrolysis, conjugation, 
410 glucuronidation, acetylation and sulfation and their activity varies with gestational 
411 age (Syme et al., 2004). Multiple cytochrome p450 (CYP) enzymes have been 
412 located within trophoblast cells of the placenta, namely CYP1A1, 3A4, 3A5, 3A7, 
413 4B1, 19 (Myllynen et al., 2009). Several studies have detected mRNA and protein 
414 levels for these enzymes in first trimester and term placenta. Uridine 5’-diphospho-
415 glucuronosyltransferases (UGTs), glutathione S-transferases (GSTs), one form of 
416 epoxide hydrolase, sulphotransferases and N-acetyltransferases mRNAs and 
417 proteins have also been found in the placenta representing metabolic phase II 
418 components. The expression levels and conformation of these enzymes in the 
419 placenta vary at different gestational stages (Rubinchik-Stern and Eyal, 2012). This 
420 metabolising activity of the placenta is another factor that controls xenochemical 
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421 transport from the mother to the fetus by regulating the quantity and make-up of 
422 metabolites (Pasanen, 1999).
423 OTC analgesics and their metabolites have known effects on the prostaglandin 
424 pathway (Anderson, 2008; Van Hecken et al., 2000; Lecomte et al., 1994). The 
425 placenta expresses components of the prostaglandin pathway, and expression 
426 patterns change with gestation and labour incidence and duration (Phillips et al., 
427 2014). Therefore, placental analgesic pharmacodynamics may alter its physiological 
428 function and pregnancy progression.
429
430 Prenatal exposure and postnatal impacts
431 Medication use in pregnancy has been an issue of high controversy. The US Food 
432 and Drug Administration (FDA), after reviewing relevant studies, announced in 2015 
433 that the evidence supporting association between analgesics and the development 
434 of ADHD in children is inconclusive (FDA, 2015). This was followed by a similar 
435 statement from the Society for Maternal-Fetal Medicine: Publications Committee in 
436 2017, clearly stating that paracetamol is safe to use during pregnancy (SMFM 
437 (Society for Maternal-Fetal Medicine Publications Committee), 2017). A year later, a 
438 press release from the Royal College of Obstetricians and Gynaecologists further 
439 assured about the definite safety of paracetamol use during pregnancy and lactation, 
440 and suggested avoidance of NSAIDs unless clinically indicated (Bisson et al., 2018; 
441 RCOG, 2018). Finally, a recent statement from the European Medicines Agency 
442 based on recommendations from the Pharmacovigilance Risk Assessment 
443 Committee (PRAC), emphasises the inconclusive nature of evidence in the literature 
444 on in utero exposure to paracetamol (European Medicines Agency (EMA), 2019). 
445 However, neither organisation cited all the relevant studies demonstrating the 
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446 potential adverse effects of analgesics in utero exposure to the offspring. Research 
447 on this topic is divided, and outcome associations should not be disregarded. 
448 Relevant literature is discussed below and summarised in Figure 3.
449
450 Neurodevelopment
451 Studies in various species have demonstrated risks in the use of analgesics during 
452 pregnancy with a focus on offspring neurodevelopmental disorders (Table 3). In 
453 mice, prenatal exposure to paracetamol disrupts brain development and behaviour 
454 (Hay-Schmidt et al., 2017; Philippot et al., 2017). More specifically, Hay-Schmidt and 
455 colleagues exposed mice in utero to paracetamol and its precursor aniline (from 7 
456 days post coitum to delivery) and found decreased cell numbers in the hypothalamus 
457 which resulted in reduced sexual behaviour, territorial display and mating in male 
458 adults. Philippot and colleagues showed that paracetamol-exposure of mice during 
459 postnatal days 3 and 10 (correlates to 3rd trimester human development) led to 
460 changes in spontaneous behaviour and habituation decrease in a new home 
461 environment in adulthood, independent of sex. Another effect of large doses of 
462 paracetamol observed in neonatal rats (3rd trimester human development) was 
463 compromise of neurotransmission, spatial memory, social behaviour and motor 
464 function (Blecharz-Klin et al., 2017); however, mice exposed to ibuprofen during the 
465 same developmental window showed no effect on behavioural pattern alterations 
466 (Philippot et al., 2016). In humans, two studies in 2014 found an association between 
467 prenatal paracetamol exposure with ADHD-like and hyperkinetic behaviours in the 
468 resulting children at ages 7 and 11 years (Liew et al., 2014; Thompson et al., 2014) . 
469 These findings are in agreement with Stergiakouli and colleagues in a longitudinal 
470 birth cohort study, reporting increased risks of multiple behavioural difficulties in the 
471 offspring after prenatal paracetamol exposure (Stergiakouli et al., 2016). A 
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472 subsequent systematic review and meta-analysis, found an overall increased risk for 
473 ADHD, autism spectrum disorders (ASD) and hyperactivity symptoms in prenatally 
474 paracetamol exposed offspring (Masarwa et al., 2018). In another systematic review 
475 and meta-analysis of 8 studies, the authors found an overall increased risk of ADHD 
476 in the offspring following paracetamol exposure during pregnancy, with higher risk 
477 ratios when consumed during the 3rd trimester or for more than 28 days (Gou et al., 
478 2019). Other studies in the past proposed an association between paracetamol, but 
479 not ibuprofen, use and increased risk of adverse neurodevelopmental outcomes in 
480 the offspring (Brandlistuen et al., 2013; Liew et al., 2016). Brandlistuen and 
481 colleagues, in a sibling-cont ol analysis of the Norwegian Mother and Child Cohort 
482 Study, showed that prenatal paracetamol exposure for more than 28 days resulted in 
483 poor gross motor development, communication, externalising and internalising 
484 behavioural problems and higher activity levels in the offspring at 3 years of age 
485 (Brandlistuen et al., 2013). Liew et al. with their 2016 study following children and 
486 mothers from the Danish National Birth Cohort for more than a decade, found 
487 increased risk for ASD with hyperkinetic symptoms in children prenatally exposed to 
488 paracetamol (Liew et al., 2016). However, zebrafish model studies of developmental 
489 paracetamol exposure failed to show the same effect, clearly demonstrating the 
490 constraints of extrapolation to humans for this type of studies (Reuter et al., 2016). A 
491 prospective cohort study of 14,062 children reported adverse association of maternal 
492 paracetamol consumption during 18 to 32 pregnancy weeks and pre-school children 
493 behaviour (Golding et al., 2019). A study using the Swedish SELMA pregnancy 
494 cohort, showed a significant association between the detection of paracetamol and 
495 its metabolites in the urine of the mothers during pregnancy with language 
496 development delays in girls at 30 months of age (Bornehag et al., 2012; Bornehag et 
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497 al., 2018). Finally, a USA retrospective study showed an association between 
498 maternal consumption of paracetamol and aspirin during pregnancy to treat flu 
499 symptoms, and the incidence of neural tube defects in the offspring (Lynberg et al., 
500 1994). 
501 Increased risk for spastic cerebral palsy after paracetamol exposure during the 
502 second pregnancy trimester and bilateral spastic cerebral palsy after exposure to 
503 aspirin was reported in a large study including 185,617 mother-children pairs from a 
504 Danish and a Norwegian cohort (Petersen et al., 2018). However, another study did 
505 not find an association, which could be due to the inclusion of preterm and very 
506 preterm babies in their analyses (Marret et al., 2010). In contrast, another study 
507 including preterm babies reported an increased risk for cerebral palsy when the 
508 mother used NSAIDs during pregnancy (Tyler et al., 2012). A longitudinal 
509 prospective study in Seattle, USA, including 421 mother/offspring pairs, showed a 
510 dose-dependent decrease in intelligence quotient (IQ) levels and attention in 4-year 
511 old children exposed to aspirin during in utero development (Streissguth et al., 
512 1987). This association was more pronounced in female than male offspring and was 
513 not significant for paracetamol exposure. However, one year later, a much larger 
514 cohort study  assessing aspirin exposure during the first 20 weeks of pregnancy in 
515 19,226 pregnancies, showed no association with adverse effects on offspring IQ 
516 (Klebanoff and Berendes, 1988). Finally, Associations between aspirin use during 
517 pregnancy and offspring psychotic episodes during adolescence have also been 
518 reported (Gunawardana et al., 2011). 
519
520 Respiratory defects
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521 Effects on the respiratory system following in utero exposure to OTC analgesics 
522 have also been reported (Table 4). A Norwegian study proposed a link between 
523 paracetamol use during pregnancy and the development of asthma in the offspring 
524 at year 3 and 7 (Magnus et al., 2016). The same study also showed positive 
525 association of asthma at 3 years of age with prenatal ibuprofen exposure. A 
526 longitudinal birth cohort study of 1,490 mother-child pairs showed associations 
527 between in utero exposure to paracetamol (but not ibuprofen) and risk of offspring 
528 recurrent wheeze and asthma in children between 3 and 5 years old (Sordillo et al., 
529 2015). However, a previous prospective follow-up study of 1,505 women-children 
530 pairs considering paracetamol use during first and third trimesters and the 
531 emergence of wheeze or asthma in the offspring until year 6, did not find an increase 
532 in the risk (Kang et al., 2009). Subsequently, in a systematic review and meta-
533 analysis, which also included the previous study, there was an overall significant 
534 association between paracetamol consumption during any trimester of pregnancy 
535 and childhood wheeze at the age of 2.5-7 years (Eyers et al., 2011). Other studies 
536 have similarly linked analgesics use during pregnancy with adverse effects on the 
537 respiratory system showing the emergence of wheeze at 1 and 5 years of age 
538 (Persky et al., 2008; Perzanowski et al., 2010).
539
540 Reproductive defects
541 A considerable effort has been focused on investigating the effects of OTC 
542 analgesics on the reproductive system, with a particular focus on male offspring due 
543 to their hypothesised androgen-disruptive effects (Table 5). Clinically relevant 
544 concentrations of analgesics have endocrine disrupting effects on the human fetal 
545 testis and alter germ cell biology (Ben Maamar et al., 2017; Mazaud-Guittot et al., 
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546 2013). Aspirin was shown to stimulate testosterone production and PGE2 levels 
547 while inhibiting production of AMH, and paracetamol reduced IGF3, INSL3 and PGE2 
548 levels. A recent study in rats by Dean and colleagues revealed that in utero exposure 
549 to paracetamol and indomethacin resulted in DNA damage and reduced fetal germ 
550 cell number in both male and female offspring (Dean et al., 2016). The first study that 
551 reported an association between maternal analgesic consumption during pregnancy 
552 and offspring cryptorchidism was a nested case-control study of 6,699 singleton 
553 neonates (Berkowitz and Lapinski, 1996). In 2011, a prospective birth cohort study 
554 including 1,954 Danish and Finnish women, assessed OTC analgesics consumption 
555 during pregnancy (Kristensen et al., 2011). They found a dose-dependent positive 
556 association between concurrent use of analgesics use during the 2nd pregnancy 
557 trimester and cryptorchidism in male offspring; however, this association was 
558 reported only for the 491 women in their Danish cohort. Specific compounds 
559 significantly associated with cryptorchidism were aspirin and paracetamol. The 
560 authors also tested the effects of mild analgesics in rats and reported a correlation 
561 between prenatal exposure with shorter anogenital distance (AGD), and reduced 
562 testicular testosterone production in males. These findings agree with a UK 
563 prospective birth cohort follow-up study in 2016, which found that in utero 
564 paracetamol exposure during 8-14 gestation weeks was associated with a shorter 
565 AGD in human male infants (Fisher et al., 2016). Another retrospective cohort study 
566 in Denmark showed the same association after NSAIDs exposure (Lind et al., 2017). 
567 AGD is a known marker for hormonal disruption through androgen exposure with 
568 links to a variety of adverse reproductive outcomes such as cryptorchidism, 
569 hypospadias, sex development disorders, lower sperm quality, testicular function and 
570 lower testosterone levels (Thankamony et al., 2016). Risk for neonatal hypospadias 
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571 was found to be increased by the use of ibuprofen and aspirin (1st trimester) by two 
572 further studies (Correy et al., 1991; Lind et al., 2013); however, other studies have 
573 not found a significant association (Hernandez et al., 2012; Slone et al., 1976; 
574 Snijder et al., 2012). In addition, experimental data from human fetal testes xenograft 
575 into mice, showed reduced testicular testosterone production following  prolonged 
576 paracetamol exposure (Van Den Driesche et al., 2015). The concurrent use of 
577 multiple analgesics in an ex vivo organotypic culture of fetal rat testis, showed 
578 specific anti-androgenic effects by inhibiting testosterone production (Kristensen et 
579 al., 2012). Another cohort study in the Netherlands reported that use of mild 
580 analgesics during the second trimester of pregnancy resulted in a higher risk for 
581 cryptorchidism, mainly associated with paracetamol use (Snijder et al., 2012). In 
582 agreement with above findings, another large Danish cohort study in 2010 reported a 
583 positive correlation between maternal paracetamol consumption during the first and 
584 second trimesters and the incidence of cryptorchidism in the offspring (Jensen et al., 
585 2010). However, Philippat and colleagues did not find a significant correlation in their 
586 cohort analysis (Philippat et al., 2011). Interestingly, a pre-conception cohort study, 
587 has shown a relationship between adult male urinary paracetamol concentration and 
588 reproductive function as higher concentration was associated with longer time to 
589 pregnancy (Smarr et al., 2016). 
590
591 Less is known about potential female-specific effects of in utero exposure to OTC 
592 analgesics (Table 5). A study by Holm and colleagues in mice, reported reduced 
593 follicular count in the ovaries of prenatally exposed female dams following 
594 paracetamol exposure (Holm et al., 2016). In utero exposed females exhibited 
595 significantly reduced fertility and premature ovarian insufficiency as adults. It has 
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596 been known for decades that paracetamol administration increases estradiol 
597 concentration in the plasma of adult women (Rogers et al., 1987), underlining a 
598 potential endocrine disruption in females similar to that in males. A recent Danish 
599 longitudinal cohort study found a positive correlation between in utero paracetamol 
600 exposure time, and earlier onset of pubertal events in the female offspring (Ernst et 
601 al., 2019). No significant association was observed in males. A recent study found a 
602 negative association between ibuprofen and ovarian cell proliferation and germ cell 
603 number, using first trimester human ovary ex vivo cultures (Leverrier-Penna et al., 
604 2018). Similarly, another study exposing fetal ovarian cultures to paracetamol or 
605 ibuprofen found significant reduction in germ cell numbers (Hurtado-Gonzalez et al., 
606 2018). The same study also tested exposure of these analgesics on fetal testes 
607 xenografted into mice and in-vitro culture, reporting similar results. Research on 
608 multiple species has shown adverse effects of aspirin and indomethacin on ovulation 
609 through prostaglandin disruption (Sirois et al., 2004). Pre-conception consumption of 
610 NSAID’s has also been associated with effects on implantation and reduced female 
611 fecundability (Mcinerney et al., 2017); however, peri-implantation use of aspirin was 
612 associated with increased fecundability (Jukic et al., 2020). Other findings in female 
613 adults include analgesic-induced disruption of menstruation and ovulation (Meyboom 
614 et al., 1995; Salman et al., 2015). Overall, more data is needed to understand the 
615 effects of analgesics on female reproductive ontogeny and function. 
616
617 Cardiovascular defects
618 Paracetamol and NSAIDs are routinely used clinically to close patent ductus 
619 arteriosus in early postnatal life; however, less is known about specific effects of 
620 prenatal exposure (Table 6). A case series analysis concluded that there was a 
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621 causal relationship between maternal paracetamol use during pregnancy and fetal 
622 ductus arteriosus constriction/closure (Allegaert et al., 2019). The same association 
623 was observed earlier in a case report in 2015 following diclofenac use during the 
624 third trimester (Aker et al., 2015). This association was further confirmed by Tanaka 
625 and colleagues through their pharmacokinetic/pharmacodynamic prediction 
626 modelling, where the impact of paracetamol and NSAIDs on fetal ductus arteriosus 
627 constriction was successfully quantified (Tanaka et al., 2016). Significant association 
628 with cardiac defects was reported after use of NSAIDs during early pregnancy in a 
629 Swedish population study (Ericson and Källén, 2001). In addition, risk for pulmonary 
630 valve stenosis, hypoplastic cleft heart syndrome and tetralogy of Fallot was found to 
631 be higher in pregnancies with consumption of paracetamol compared to NSAIDs 
632 (Interrante et al., 2017). 
633
634 Renal outcomes 
635 In utero exposure to OTC analgesics have been associated with adverse effects on 
636 fetal urinary tract function (Table 7). A report of two cases of long-term exposure to 
637 diclofenac during pregnancy, proposed a causal relationship with fetal 
638 oligohydramnios during the second trimester, as the effect was reversible following 
639 discontinuation of use (Scherneck et al., 2015). An irreversible association of 
640 diclofenac with neonatal oliguria and renal failure in the offspring was described by a 
641 report of 3 cases (Phadke et al., 2012). On the other hand, a clinical trial reported no 
642 effect of low-dose aspirin to neither offspring amniotic fluid volume nor fetal urine 
643 output (Maher et al., 1993). Paracetamol exposure during the third trimester was 
644 also not found to have a significant association with fetal renal toxicity in a 
645 prospective cohort study (Dathe et al., 2019).




647 Other perinatal outcomes 
648 Adverse effects on the offspring at birth have also been associated with in utero 
649 analgesics exposure (Table 8). A study by Werler and colleagues demonstrated a 
650 significant association between paracetamol use during the first trimester of 
651 pregnancy and the development of amniotic band defects (Werler et al., 2003). In 
652 another case-control study by the same group, gastroschisis was associated with 
653 paracetamol and aspirin use during early pregnancy and was independent from 
654 maternal symptoms (Werler et al., 2002). An increased risk for gastroschisis was 
655 also reported in infants after aspirin exposure during the first trimester of pregnancy 
656 in a meta-analysis of the literature (Kozer et al., 2002). These results were in 
657 agreement with a previous study by Torfs and colleagues, associating aspirin and 
658 ibuprofen (but not paracetamol) consumption during pregnancy with increased risk 
659 for gastroschisis (Torfs et al., 1996). Conversely, diclofenac use during the first was 
660 not found to have a significant association with major birth defects (Cassina et al., 
661 2010; Padberg et al., 2018). Similar results were also reported for use of multiple 
662 NSAIDs during the first 12 weeks of gestation where no association with major birth 
663 defects in the offspring was found (van Gelder et al., 2011). A USA cohort study 
664 comparing the incidence of birth defects between the use of NSAIDs and 
665 paracetamol, showed that NSAID consumption during pregnancy can result in higher 
666 risk for gastroschisis, hypospadias, cleft palate, cleft lip, anencephaly and spina 
667 bifida than paracetamol in-utero exposure (Interrante et al., 2017). On the other 
668 hand, two studies reporting 60 and 300 cases of paracetamol overdose during 
669 pregnancy, did not show strong associations with fetal toxicity or other adverse 
670 outcomes (Riggs et al., 1989; McElhatton et al., 1997). It should be noted that these 
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671 women were treated for overdoses with N-acetylcysteine, ipecac or methionine. 
672 Finally, no association was observed with paracetamol use and general fetal growth 




677 Considerable effort has been focussed on pregnancy-specific outcomes following 
678 OTC exposure (Table 9). A case-control study in Denmark reported an increased 
679 risk of miscarriage after the use of NSAIDs during pregnancy, with the highest risk 
680 when consumed 1 week before the miscarriage (Nielsen et al., 2001). Two years 
681 later, another cohort study in San Francisco, USA, provided similar findings, with a 
682 higher risk of miscarriage reported following prenatal exposure to NSAIDs and 
683 aspirin, however, not paracetamol (Li et al., 2003). In contrast, a cohort study in 
684 Germany did not find any significant association between ibuprofen exposure during 
685 the first trimester and major birth defects in the offspring or spontaneous abortion 
686 rates (Dathe et al., 2018). The same results were observed in another German study 
687 using the same cohort, but considering diclofenac use during pregnancy (Padberg et 
688 al., 2018). Spontaneous abortion was also not significantly associated with multiple 
689 NSAID consumption either during pregnancy or periconceptional in two further 
690 cohort studies (Daniel et al., 2014; Edwards et al., 2012). In addition, when 
691 considering aspirin only, a meta-analysis of randomised controlled studies showed 
692 no significant association with miscarriage rates (Kozer et al., 2003). A positive 
693 association was however reported by a case-control study considering multiple 
694 NSAIDs and spontaneous abortion risk (Nakhai-Pour et al., 2011). Finally, a 
695 retrospective cohort study, also in Germany, showed that maternal paracetamol 
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696 intake during the third trimester of pregnancy was positively associated with lower 
697 numbers of hematopoietic stem cells in cord blood (Bremer et al., 2017).
698
699 Discussion
700 There is a high prevalence of self-medication during pregnancy, which increases 
701 annually (Mosley et al., 2015; Van Calsteren et al., 2016). Our review of the current 
702 literature revealed that pregnant women of the Western world are using OTC 
703 medications more frequently. This observation is in agreement with previous findings 
704 of Baraka and colleagues in their multi-ethnicity cohort of pregnant women (Baraka 
705 et al., 2013). In utero exposure is therefore ubiquitous. OTC medication abundance, 
706 ease of access, low cost, limited dose and side-effects awareness, general Western 
707 lifestyle, improper record keeping and frequent lack of adequate advice from 
708 healthcare professionals, make this exposure hard to quantify. This results in a 
709 series of studies basing their findings on data that may not be accurate, and suffer 
710 from different types of bias. Several OTC medications meant for other purposes can 
711 also contain doses of analgesics (e.g. cold and flu remedies), and simultaneous 
712 consumption might therefore have synergistic effects or lead to surpass of 
713 recommended doses.  In addition to drug consumption, environmental influences 
714 can also play an important role, for example aniline. This compound is an industrial 
715 chemical that can be found in the air, water, dietary products and synthetic products 
716 such as rubbers, dyes, pesticides, diphenylamine or synthetic fibres. Aniline is 
717 rapidly converted into paracetamol by the human liver (Holm et al., 2015). Therefore, 
718 in-utero exposure may not only be limited to maternal consumption of the analgesic, 
719 complicating exposure analysis studies further. The potential for other 
720 pharmaceuticals or environmental endocrine disruptor mixtures to modulate effects 
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721 of analgesics could also be true, but this has not been explored by human studies to 
722 date.
723
724 Many analgesics freely cross the placenta and reach the developing fetus. We know 
725 this occurs mostly by measurements of the compounds and their metabolites in fetal 
726 plasma/meconium/amniotic fluid. Something that is still not fully understood is 
727 whether all metabolites have the ability to cross the placenta to the same degree, at 
728 the same speed and which of them might be responsible for the observed adverse 
729 outcomes in the offspring for each compound. In Figure 4 we summarise a 
730 hypothesis of all the possible routes that could connect maternal consumption to 
731 postnatal ill health. Whether one, a combination, or all could be correct requires 
732 further research. This hypothesis can be relevant to any type of medication or 
733 combination of different compounds. As shown by many of the cited studies, during 
734 the course of their pregnancy, women often use more than one compound either at 
735 different times or in combination. Combining different analgesics or exceeding 
736 recommended doses can sometimes be unintentional as many of these agents are 
737 included in other medications that are also available OTC. Mixing different 
738 analgesics together, even though it can be part of a therapeutic regimen for certain 
739 indications such as severe pain, can also lead to drug interactions with substantial 
740 health risks (Mark et al., 2008). Inevitably, when it comes to OTC medications, this 
741 risk is elevated. The combination of analgesic compounds in pregnancy can 
742 therefore put the fetus at risk for toxicity, leading to adverse health outcomes that 
743 may be a result of of two or more exposures. Almost certainly, whether due to 
744 exposure to one or multiple compounds, different fetal organ systems will be affected 
745 via different pathways and mechanisms, and possibly at different levels of exposure. 
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746 On the other hand, fetal programming can occur by alterations in the placenta alone 
747 through exposure (Kratimenos and Penn, 2019). Therefore, another potential 
748 hypothesis might be that accumulation of OTC compounds in the placenta can 
749 indirectly result in fetal programming via alterations in placental function. Gädeke first 
750 described in the early 70’s what is now general knowledge, that xenobiotic 
751 metabolism is altered with life stage (age), with fetuses and neonates being more 
752 susceptible than adults (Gädeke, 1972; Allegaert et al., 2008). The basis of this 
753 observation could be alterations in pharmacokinetics and pharmacodynamics 
754 between different gestational stages resulting from a different drug metabolising 
755 enzyme expression profile. In addition, adult drug metabolism is sexually dimorphic, 
756 which is something that is likely to also be true during fetal life. This aspect is 
757 overlooked by the majority of current literature and pharmaceutical companies. 
758 Therefore, toxicity of metabolites might be completely different considering the 
759 altered pharmacodynamics/pharmacokinetics of drug compounds during pregnancy 
760 and fetal life/sex and the lack of adequate knowledge to understand drug metabolism 
761 at this developmental stage.
762
763 The liver, kidney and intestine are the major organs that metabolise paracetamol and 
764 NSAIDs in the adult. However, all organ systems have at least mild metabolic 
765 activity. For instance paracetamol is oxidised to NAPQI by rat brain cells in situ 
766 (Howard et al., 2003). Drug metabolising enzymes are also expressed in adrenals, 
767 lungs, heart, ovaries, testes, prostate, skin and placenta (Xinxin and Laurence, 2003; 
768 Du et al., 2006; Biéche et al., 2007). Reviewed literature presented here, suggests 
769 neurodisruptive and endocrine disruptive properties of in utero exposure to 
770 analgesics. The higher frequency of male reproductive outcomes so far reported 
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771 could be explained by sex-specific endocrine disruption and/or abnormal androgen 
772 endocrinology during fetal life. 
773
774 Another plausible explanation for the adverse effects of analgesics could be via their 
775 association with prostaglandins. Prostaglandins are important components for 
776 pregnancy and parturition as they stimulate uterine contractions and enhance 
777 cervical ripening. NSAIDs inhibit cyclo-oxygenase (COX) enzymes and therefore 
778 downregulate prostaglandin synthesis and prolong gestation and labour. Premature 
779 labour can be successfully prevented using ibuprofen, aspirin, diclofenac and 
780 ketoprofen, all available ove -the-counter (Dawood, 1993; Lewis and Schulman, 
781 1973). These properties could therefore explain the observed associations of their 
782 use during pregnancy and miscarriage. Prostaglandins are also important regulators 
783 of embryonic and fetal reproductive development as demonstrated in mice models 
784 (Gupta, 1989; Gupta and Goldman, 1986). Inhibition of the prostaglandin pathway 
785 during gestation can therefore also interact with human fetal reproductive system 
786 development, leading to the observed neonatal reproductive outcomes. Despite their 
787 well-understood functions, little information is available about COX enzyme 
788 expression and role during fetal life. A rat study showed their expression in fetal skin, 
789 cartilage, brain, heart and kidney (Stanfield et al., 2003), while experiments using 
790 transgenic mice demonstrated the importance of COX2 in normal fetal development 
791 (Shim et al., 2010). Reported outcomes of in utero exposure could therefore be due 
792 to tissue-specific inhibition of COX enzymes, possibly dependant on gestation, 
793 quantity and frequency of exposure. 
794
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795 Pharmacokinetics and pharmacodynamics are altered during pregnancy through a 
796 series of physiological changes (Loebstein et al., 1997; Sen et al., 1998). These 
797 changes should be considered by physicians for adjustments in drug dosage and 
798 frequency during this time to ensure the safety of the mother, which is unfortunately 
799 very difficult in practice (Costantine, 2014). In the context of analgesics, there is 
800 significant increase in paracetamol clearance during pregnancy, leading to a faster 
801 decrease of its therapeutic effects. However, in an attempt to increase efficacy, 
802 higher doses could lead to a proportional increase in oxidation into toxic metabolites 
803 (Allegaert and van den Anker, 2017). There is no study, to our knowledge, 
804 investigating differential pregnancy dosing of analgesics. Nevertheless, in the single 
805 systematic review on the topic, the authors reported significant pharmacokinetic 
806 changes between pregnant and non-pregnant women for paracetamol, emphasizing 
807 the need for further research to address the need for drug optimisation for pregnancy 
808 (Pariente et al., 2016).
809
810 Disturbed prenatal programming can, therefore, occur through either fetal tissue 
811 toxicity by the accumulation of toxic metabolites or disruption of physiological 
812 processes and normal development through the inhibition of prostaglandin synthesis. 
813 Considering the current literature, no definite conclusions can be drawn. Although 
814 results from many studies are consistent, interpretations should be made with 
815 caution and future studies should pursue this important set of associations with 
816 further research. We cannot say confidently that OTC analgesics are indeed a direct 
817 cause of all observed offspring outcomes. All discussed research demonstrates the 
818 challenges of conducting this type of exposure studies, exemplifies the difficulty of 
819 accounting for other unmeasured environmental influences and genetics, and 
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820 underlines the need of follow-up studies on larger cohorts considering a wider time 
821 window. Precise assessment of exposure including dose, timing and duration of use 
822 during pregnancy is what is mostly missing from current literature and should be 
823 included in designing future studies. Parallel research on the effects of the 
824 underlying maternal conditions that require analgesics consumption should also rule 
825 out whether associations are indeed a matter of analgesics exposure or a result of 
826 physiological response/adaptation to maternal health status.
827
828 Another hurdle to definitive decision making is that most studies looking into OTC 
829 analgesic exposure during pregnancy might suffer from confounding of their results 
830 by indication for use. While many results for the same compound are consistent 
831 between studies in large cohorts, underlying acute or chronic maternal health 
832 conditions are overlooked by the majority. This is a very important point for 
833 consideration in the design of future studies, however, it is challenging to tackle due 
834 to the difficulty of accurate quantification of data on such high prevalence of 
835 consumption and subjective decision-making by the mothers.
836
837 More data focusing on specific pregnancy timing of consumption are needed to 
838 identify developmental windows of sensitivity for different compounds and the 
839 associated offspring outcomes. Information on analgesic consumption during very 
840 early pregnancy should also be collected from pre-pregnancy cohorts, as analgesic 
841 use before and while trying to conceive could then be assessed and tracked more 
842 easily after the pregnancy is known. Few prospective pregnancy cohorts are 
843 currently available (e.g. EARTH, Messerlian et al., 2018, and ALSPAC, Lawlor et al., 
844 2019); however, to the best of our knowledge, there is no published literature 
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845 concerning OTC analgesics use in these cohorts. Research including multiple 
846 exposure models would shed light into gene-environment and immune-environment 
847 interactions. In addition, focus should be given into research to elucidate the 
848 underlying mechanisms and develop safer analgesics. Over two decades ago, 
849 designing a study that includes human fetal samples appeared impossible, directing 
850 the field towards live animal models for in vivo studies (Ring et al., 1999). We are 
851 now able to obtain valuable fresh tissue samples from human fetuses coming from 
852 elective pregnancy terminations. These tissues can be analysed morphologically and 
853 used for genomics/proteomics and culture investigations, with a focus on gestational 
854 stage/s of exposure and fetal sex (Hurtado-Gonzalez et al., 2018). While more 
855 research is needed, current technological and practical tools make real progress in 
856 understanding gestation risks of analgesics and other drugs more likely than ever 
857 before. 
858
859 Even though literature evidence considering different offspring outcomes following in 
860 utero analgesics exposure is conflicting, the presence of studies showing definite 
861 associations should not be overlooked. Pain and fever management during 
862 pregnancy should always be considered, but health risks versus benefits for both the 
863 mother and the fetus must be considered. One realistic approach is caution against 
864 their indiscriminate use to ensure the minimum effective dose is administered for the 
865 shortest possible time. Given their routine use, OTC analgesic consumption during 
866 pregnancy requires further in-depth study so that the public health implications are 
867 understood and the potential negative effects are minimised.
868
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1663 Figure 1. Prevalence of analgesics consumption during pregnancy from different 
1664 parts of the world. Percentages summarised here as reported by the literature. More 
1665 details on each study can be found in Table 1 and in text.
1666
1667 Figure 2. Schematic diagram of the major drug transporters on human placental 
1668 syncytiotrophoblast and their substrates according to medication type. Solute-linked 
1669 carrier (SLC) (blue) and adenosine triphosphate binding cassette (ABC) transporters 
1670 (red). Phase I metabolising enzymes (P1); phase II metabolising enzymes (P2). 
1671 Arrow direction demonstrates influx/efflux. Note that not all substrates have been 
1672 examined in the human placenta. Figure was prepared based on information cited in 
1673 this review. * exact placental membrane localisation not known; † localised on both 
1674 membranes
1675
1676 Figure 3. OTC analgesic exposures during pregnancy and their associations with 
1677 adverse offspring health outcomes from current literature. Indication of references 
1678 according to study type: * Cohort Studies, § Case-control/Case Report Studies, ¥ 
1679 Systematic reviews/Meta-analyses, † Experimental Studies
1680
1681 Figure 4. Hypothesis of different routes of analgesics and their metabolites during 
1682 pregnancy.
1683
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